Anti-thrombotic therapy in infective endocarditis

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 9, 2011, Pages 1203-1219

  Vanassche, Thomas ^a   Peetermans, Willy E ^b   Herregods, Marie Christine ^b   Herijgers, Paul ^c   Verhamme, Peter ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

anti thrombotic treatment; anticoagulation; antiplatelet treatment; embolization; infective endocarditis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; BACTERIAL ENDOCARDITIS; EARLY DIAGNOSIS; EMBOLISM; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; DISEASE MODELS, ANIMAL; EMBOLISM; ENDOCARDITIS, BACTERIAL; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS;

EID: 80053094198     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.100     Document Type: Review

References (82)

1. Thuny F, Avierinos JF, Tribouilloy C et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur. Heart J. 28(9), 1155-1161 (2007). (Pubitemid 47343863)
2. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch. Intern. Med. 160(18), 2781-2787 (2000).
3. Thuny F, Di Salvo G, Belliard O et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 112(1), 69-75 (2005). (Pubitemid 40962571)
4. Anderson DJ, Goldstein LB, Wilkinson WE et al. Stroke location, characterization, severity, and outcome in mitral vs aortic valve endocarditis. Neurology 61(10), 1341-1346 (2003). (Pubitemid 37463367)
5. Cooper HA, Thompson EC, Laureno R et al. Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. Circulation 120(7), 585-591 (2009).
6. Van Riet J, Hill EE, Gheysens O et al. (18)F-FDG PET/CT for early detection of embolism and metastatic infection in patients with infective endocarditis. Eur. J. Nucl. Med. Mol. Imaging 37(6), 1189-1197 (2010).
7. Saxena A, Aggarwal N, Gupta P, Juneja R, Kothari SS, Math R. Predictors of embolic events in pediatric infective endocarditis. Indian Heart J. 61(3), 242-245 (2009).
8. Lepur D, Barsic B. Incidence of neurological complications in patients with native-valve infective endocarditis and cerebral microembolism: an open cohort study. Scand. J. Infect. Dis. 41(10), 708-713 (2009).
9. Hill EE, Herijgers P, Claus P, Vanderschueren S, Peetermans WE, Herregods MC. Clinical and echocardiographic risk factors for embolism and mortality in infective endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 27(12), 1159-1164 (2008).
10. Paschalis C, Pugsley W, John R, Harrison MJ. Rate of cerebral embolic events in relation to antibiotic and anticoagulant therapy in patients with bacterial endocarditis. Eur. Neurol. 30(2), 87-89 (1990). (Pubitemid 20104218)
11. Hart RG, Foster JW, Luther MF, Kanter MC. Stroke in infective endocarditis. Stroke 21(5), 695-700 (1990). (Pubitemid 20180790)
12. Durante Mangoni E, Adinolfi LE, Tripodi MF et al. Risk factors for major embolic events in hospitalized patients with infective endocarditis. Am. Heart J. 146(2), 311-316 (2003). (Pubitemid 36951777)
13. Buyukasyk NS, Ileri M, Alper A et al. Increased blood coagulation and platelet activation in patients with infective endocarditis and embolic events. Clin. Cardiol. 27(3), 154-158 (2004). (Pubitemid 38269658)
14. Dickerman SA, Abrutyn E, Barsic B et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am. Heart J. 154(6), 1086-1094 (2007). (Pubitemid 350123526)
15. Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur. Heart J. 30(19), 2369-2413 (2009).
16. Delahaye F. Is early surgery beneficial in infective endocarditis? A systematic review. Arch. Cardiovasc. Dis. 104(1), 35-44 (2011).
17. Thuny F, Habib G. When should we operate on patients with acute infective endocarditis? Heart 96(11), 892-897 (2010).
18. Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? Circulation 121(9), 1141-1152 (2010).
19. Gutierrez-Martin MA, Galvez-Aceval J, Araji OA. Indications for surgery and operative techniques in infective endocarditis in the present day. Infect. Disord. Drug Targets 10(1), 32-46 (2010).
20. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology Stroke and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111(23), e394-e434 (2005).
21. Hill EE, Herregods MC, Vanderschueren S, Claus P, Peetermans WE, Herijgers P. Outcome of patients requiring valve surgery during active infective endocarditis. Ann. Thorac. Surg. 85(5), 1564-1569 (2008). (Pubitemid 351618360)
22. Thiene G, Basso C. Pathology and pathogenesis of infective endocarditis in native heart valves. Cardiovasc. Pathol. 15(5), 256-263 (2006). (Pubitemid 44345241)
23. Widmer E, Que YA, Entenza JM, Moreillon P. New concepts in the pathophysiology of infective endocarditis. Curr. Infect. Dis. Rep. 8(4), 271-279 (2006). (Pubitemid 44069996)
24. Moreillon P, Que YA. Infective endocarditis. Lancet 363(9403), 139-149 (2004). (Pubitemid 38068333)
25. Veltrop MH, Beekhuizen H. Monocytes maintain tissue factor activity after cytolysis of bacteria-infected endothelial cells in an in vitro model of bacterial endocarditis. J. Infect. Dis. 186(8), 1145-1154 (2002). (Pubitemid 35177118)
26. Heying R, van de Gevel J, Que YA, Piroth L, Moreillon P, Beekhuizen H. Contribution of (sub)domains of Staphylococcus aureus fibronectin-binding protein to the proinflammatory and procoagulant response of human vascular endothelial cells. Thromb. Haemost. 101(3), 495-504 (2009).
27. Ford I, Douglas CW. The role of platelets in infective endocarditis. Platelets 8(5), 285-294 (1997). (Pubitemid 27485401)
28. Friedrich R, Panizzi P, Fuentes-Prior P et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425(6957), 535-539 (2003). (Pubitemid 37237051)
29. Vanassche T, Verhaegen J, Peetermans WE, Hoylaerts MF, Verhamme P. Dabigatran inhibits Staphylococcus aureus coagulase activity. J. Clin. Microbiol. 48(11), 4248-4250 (2010).
30. Bonow RO, Carabello BA, Kanu C et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114(5), e84-e231 (2006). (Pubitemid 44268973)
31. Thill CJ, Meyer OO. Experiences with penicillin and dicumarol in the treatment of subacute bacterial endocarditis. Am. J. Med. Sci. 213(3), 300-307 (1947).
32. Priest WS, Smith JM, Mc GC. The effect of anticoagulants on the penicillin therapy and the pathologic lesions of subacute bacterial endocarditis. N. Engl. J. Med. 235(20), 699-706 (1946).
33. Meyer OO, Thill CJ. Penicillin and dicumarol, and penicillin in the treatment of subacute bacterial endocarditis. Proc. Annu. Meet Cent. Soc. Clin. Res. USA 18, 31 (1945).
34. Loewe L. The combined use of anti-infectives and anticoagulants in the treatment of subacute bacterial endocarditis. Bull. NY Acad. Med. 21(2), 59-86 (1945).
35. Wilson WR, Geraci JE, Danielson GK et al. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation 57(5), 1004-1007 (1978). (Pubitemid 8339846)
36. Davenport J, Hart RG. Prosthetic valve endocarditis 1976-1987. Antibiotics, anticoagulation, and stroke. Stroke 21(7), 993-999 (1990). (Pubitemid 20218160)
37. Delahaye JP, Poncet P, Malquarti V, Beaune J, Gare JP, Mann JM. Cerebrovascular accidents in infective endocarditis: role of anticoagulation. Eur. Heart J. 11(12), 1074-1078 (1990).
38. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch. Intern. Med. 159(5), 473-475 (1999). (Pubitemid 29108912)
39. Rasmussen RV, Snygg-Martin U, Olaison L et al. Major cerebral events in Staphylococcus aureus infective endocarditis: is anticoagulant therapy safe? Cardiology 114(4), 284-291 (2009).
40. Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L. Warfarin therapy and incidence of cerebrovascular complications in left-sided native valve endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 30(2), 151-157 (2011).
41. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
42. Johnson CM, Bowie EJ. Pigs with von Willebrand disease may be resistant to experimental infective endocarditis. J. Lab. Clin. Med. 120(4), 553-558 (1992).
43. Pujadas R, Escriva E, Fernandez F et al. [Effect of various doses of aspirin on the development of aseptic thrombotic aortic endocarditis experimentally induced in the rabbit]. Rev. Esp. Cardiol. 41(1), 31-34 (1988). (Pubitemid 18074402)
44. Kessler CM, Nussbaum E, Tuazon CU. In vitro correlation of platelet aggregation with occurrence of disseminated intravascular coagulation and subacute bacterial endocarditis. J. Lab. Clin. Med. 109(6), 647-652 (1987). (Pubitemid 17093158)
45. Sullam PM, Bayer AS, Foss WM, Cheung AL. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect. Immun. 64(12), 4915-4921 (1996). (Pubitemid 26403941)
46. Yeaman MR, Sullam PM, Dazin PF, Norman DC, Bayer AS. Characterization of Staphylococcus aureus-platelet binding by quantitative flow cytometric analysis. J. Infect. Dis. 166(1), 65-73 (1992).
47. Douglas CW, Brown PR, Preston FE. Platelet aggregation by oral streptococci. FEMS Microbiol. Lett. 60(1-2), 63-67 (1990). (Pubitemid 20350691)
48. Ford I, Douglas CW, Preston FE, Lawless A, Hampton KK. Mechanisms of platelet aggregation by Streptococcus sanguis, a causative organism in infective endocarditis. Br. J. Haematol. 84(1), 95-100 (1993). (Pubitemid 23158121)
49. Herzberg MC. Platelet-streptococcal interactions in endocarditis. Crit. Rev. Oral Biol. Med. 7(3), 222-236 (1996). (Pubitemid 26363852)
50. Sande MA, Scheld WM. Bacterial adherence in endocarditis: interaction of bacterial dextran, platelets, fibrin, and antibody. Scand. J. Infect. Dis. 24(Suppl.), 100-105 (1980). (Pubitemid 11180785)
51. Herzberg MC, MacFarlane GD, Gong K et al. The platelet interactivity phenotype of Streptococcus sanguis influences the course of experimental endocarditis. Infect. Immun. 60(11), 4809-4818 (1992).
52. Farber BF, Wolff AG. The use of nonsteroidal antiinflammatory drugs to prevent adherence of Staphylococcus epidermidis to medical polymers. J. Infect. Dis. 166(4), 861-865 (1992).
53. Nicolau DP, Freeman CD, Nightingale CH et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect. Immun. 61(4), 1593-1595 (1993). (Pubitemid 23099245)
54. Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. Influence of ticlopidine on the development of experimental Staphylococcus aureus endocarditis. Int. J. Antimicrob. Agents 7(4), 271-274 (1996). (Pubitemid 26426000)
55. Nicolau DP, Tessier PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int. J. Antimicrob. Agents 11(2), 159-161 (1999). (Pubitemid 29114976)
56. Kupferwasser LI, Yeaman MR, Shapiro SM et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 99(21), 2791-2797 (1999). (Pubitemid 29250026)
57. Kupferwasser LI, Yeaman MR, Nast CC et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J. Clin. Invest. 112(2), 222-233 (2003). (Pubitemid 38056358)
58. Yeaman MR, Norman DC, Bayer AS. Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob. Agents Chemother. 36(8), 1665-1670 (1992).
59. Yeaman MR, Norman DC, Bayer AS. Staphylococcus aureus susceptibility to thrombin-induced platelet microbicidal protein is independent of platelet adherence and aggregation in vitro. Infect. Immun. 60(6), 2368-2374 (1992).
60. Yeaman MR, Sullam PM, Dazin PF, Bayer AS. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect. Immun. 62(8), 3416-3423 (1994). (Pubitemid 24232128)
61. Kupferwasser LI, Yeaman MR, Shapiro SM, Nast CC, Bayer AS. In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental Staphylococcus aureus endocarditis: microbiological, histopathologic, and echocardiographic analyses. Circulation 105(6), 746-752 (2002). (Pubitemid 34157380)
62. Dankert J, van der Werff J, Zaat SA, Joldersma W, Klein D, Hess J. Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Infect. Immun. 63(2), 663-671 (1995).
63. Dankert J, Krijgsveld J, van Der Werff J, Joldersma W, Zaat SA. Platelet microbicidal activity is an important defense factor against viridans streptococcal endocarditis. J. Infect. Dis. 184(5), 597-605 (2001). (Pubitemid 32783551)
64. Bayer AS, Cheng D, Yeaman MR et al. In vitro resistance to thrombin-induced platelet microbicidal protein among clinical bacteremic isolates of Staphylococcus aureus correlates with an endovascular infectious source. Antimicrob. Agents Chemother. 42(12), 3169-3172 (1998). (Pubitemid 28553737)
65. Fowler VG Jr, McIntyre LM, Yeaman MR et al. In vitro resistance to thrombin-induced platelet microbicidal protein in isolates of Staphylococcus aureus from endocarditis patients correlates with an intravascular device source. J. Infect. Dis. 182(4), 1251-1254 (2000).
66. Mercier RC, Dietz RM, Mazzola JL, Bayer AS, Yeaman MR. Beneficial influence of platelets on antibiotic efficacy in an in vitro model of Staphylococcus aureus-induced endocarditis. Antimicrob. Agents Chemother. 48(7), 2551-2557 (2004). (Pubitemid 38823424)
67. Zhang X, Liu Y, Gao Y et al. Inhibiting platelets aggregation could aggravate the acute infection caused by Staphylococcus aureus. Platelets 22(3), 228-236 (2011).
68. Taha TH, Durrant SS, Mazeika PK, Nihoyannopoulos P, Oakley CM. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J. Intern. Med. 231(5), 543-546 (1992).
69. Chan KL, Dumesnil JG, Cujec B et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J. Am. Coll. Cardiol. 42(5), 775-780 (2003). (Pubitemid 37059731)
70. Chan KL, Tam J, Dumesnil JG et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin. Infect. Dis. 46(1), 37-41 (2008). (Pubitemid 351263557)
71. Anavekar NS, Tleyjeh IM, Mirzoyev Z et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin. Infect. Dis. 44(9), 1180-1186 (2007). (Pubitemid 46651242)
72. Eisen DP, Corey GR, McBryde ES et al. Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J. Infect. 58(5), 332-338 (2009).
73. Pepin J, Tremblay V, Bechard D et al. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin. Microbiol. Infect. 15(2), 193-199 (2009).
74. Sedlacek M, Gemery JM, Cheung AL, Bayer AS, Remillard BD. Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. Am. J. Kidney Dis. 49(3), 401-408 (2007).
75. Salem DN, OGara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.), 593S-629S (2008). (Pubitemid 351892973)
76. Verhamme P, Hoylaerts MF. Hemostasis and inflammation: two of a kind? Thromb. J. 7, 15 (2009).
77. Cremieux AC, Carbon C. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrob. Agents Chemother. 36(10), 2069-2074 (1992).
78. Leport C, Vilde JL, Bricaire F et al. Fifty cases of late prosthetic valve endocarditis: improvement in prognosis over a 15 year period. Br. Heart J. 58(1), 66-71 (1987). (Pubitemid 17100160)
79. Carpenter JL, McAllister CK. Anticoagulation in prosthetic valve endocarditis. South Med. J. 76(11), 1372-1375 (1983). (Pubitemid 14203645)
80. Levison ME, Carrizosa J, Tanphaichitra D, Schick PK, Rubin W. Effect of aspirin on thrombogenesis and on production of experimental aortic valvular Streptococcus viridans endocarditis in rabbits. Blood 49(4), 645-650 (1977). (Pubitemid 8080194)
81. Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 39(8), 1748-1751 (1995).
82. Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis. Int. J. Antimicrob. Agents 9(4), 227-229 (1998). (Pubitemid 28152352)